Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MCRB Seres Therapeutics	$19.44 +6.1%	$12.90	$6.53 ▼ $26.40	$160.38M	2.9	130,348 shs	167,878 shs
ORKA Oruka Therapeutics	$15.44 +4.4%	$13.56	$5.49 ▼ $52.32	$553.90M	-0.35	142,141 shs	152,697 shs
TRML Tourmaline Bio	$23.31 +1.1%	$19.39	$11.56 ▼ $29.79	$592.31M	2.04	213,340 shs	126,071 shs
TYRA Tyra Biosciences	$11.71 +0.1%	$10.38	$6.42 ▼ $29.60	$624.11M	1.08	205,397 shs	242,316 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MCRB Seres Therapeutics	+6.11%	+16.48%	+48.51%	+153.46%	+11.19%
ORKA Oruka Therapeutics	+4.39%	+0.46%	+6.19%	+41.00%	+1,543,999,900.00%
TRML Tourmaline Bio	+1.08%	+3.28%	+23.07%	+52.15%	+60.10%
TYRA Tyra Biosciences	+0.09%	+9.13%	+8.33%	+26.05%	-48.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MCRB Seres Therapeutics	3.2512 of 5 stars	2.9	1.0	4.6	2.7	0.8	0.0
ORKA Oruka Therapeutics	2.3011 of 5 stars	3.6	0.0	0.0	1.0	2.5	0.6
TRML Tourmaline Bio	2.358 of 5 stars	3.5	2.0	0.0	2.4	2.5	0.0
TYRA Tyra Biosciences	2.2866 of 5 stars	3.5	1.0	0.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MCRB Seres Therapeutics	1.75	Reduce	$73.67	278.94% Upside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	161.50% Upside
TRML Tourmaline Bio	3.00	Buy	$50.14	115.11% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	163.31% Upside

Current Analyst Ratings Breakdown

Latest MCRB, TRML, ORKA, and TYRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
8/18/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
8/14/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
8/14/2025	TRML Tourmaline Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
7/23/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/21/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MCRB Seres Therapeutics	$126.32M	1.35	N/A	N/A	$3.76 per share	5.17
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.10 per share	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.09 per share	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$5.67 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	N/A
ORKA Oruka Therapeutics	-$83.72M	-$2.81	N/A	N/A	N/A	N/A	-26.26%	-24.16%	N/A
TRML Tourmaline Bio	-$73.21M	-$3.43	N/A	N/A	N/A	N/A	-30.50%	-29.63%	11/6/2025 (Estimated)
TYRA Tyra Biosciences	-$86.48M	-$1.78	N/A	N/A	N/A	N/A	-31.22%	-29.49%	11/6/2025 (Estimated)

Latest MCRB, TRML, ORKA, and TYRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TYRA Tyra Biosciences	-$0.53	-$0.47	+$0.06	-$0.47	N/A	N/A
8/13/2025	Q2 2025	TRML Tourmaline Bio	-$0.94	-$0.90	+$0.04	-$0.90	N/A	N/A
8/11/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.48	-$0.46	+$0.02	-$0.46	N/A	N/A
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MCRB Seres Therapeutics	N/A	1.57	1.57
ORKA Oruka Therapeutics	N/A	27.42	27.42
TRML Tourmaline Bio	N/A	24.68	24.68
TYRA Tyra Biosciences	N/A	21.94	22.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MCRB Seres Therapeutics	59.34%
ORKA Oruka Therapeutics	56.44%
TRML Tourmaline Bio	91.89%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
MCRB Seres Therapeutics	4.70%
ORKA Oruka Therapeutics	24.69%
TRML Tourmaline Bio	13.00%
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable
ORKA Oruka Therapeutics	N/A	37.45 million	28.20 million	N/A
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable
TYRA Tyra Biosciences	20	53.30 million	45.20 million	Optionable

MCRB, TRML, ORKA, and TYRA Headlines

Recent News About These Companies

Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) PT at $30.83

August 23 at 2:47 AM | americanbankingnews.com

Tyra Biosciences initiates paediatric study for achondroplasia treatment

August 22 at 7:31 AM | finance.yahoo.com

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

August 21 at 8:00 AM | prnewswire.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Buy" from Analysts

August 21 at 2:22 AM | marketbeat.com

Tyra Biosciences Announces Participation at Upcoming Investor Events

August 20 at 4:05 PM | prnewswire.com

DelveInsight Business Research, LLP: FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsight

August 20 at 5:13 AM | finanznachrichten.de

FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsight

August 19, 2025 | finance.yahoo.com

Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?

August 19, 2025 | zacks.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Here's What Happened

August 17, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up After Strong Earnings

August 17, 2025 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Releases Earnings Results, Beats Estimates By $0.06 EPS

August 16, 2025 | marketbeat.com

Tyra Biosciences reports Q2 EPS (47c), consensus (51c)

August 14, 2025 | msn.com

Tyra Biosciences Narrows Loss in Q2

August 14, 2025 | aol.comA

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

August 14, 2025 | prnewswire.com

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

August 7, 2025 | uk.finance.yahoo.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short Interest

August 2, 2025 | marketbeat.com

Tyra Biosciences (TYRA) to Release Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Buy" by Brokerages

July 26, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Trading Down 3% - Here's Why

July 23, 2025 | marketbeat.com

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

July 21, 2025 | prnewswire.com

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Morningstar

July 9, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, TRML, ORKA, and TYRA Company Descriptions

Seres Therapeutics NASDAQ:MCRB

$19.44 +1.12 (+6.11%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.39 -0.05 (-0.26%)

As of 08/22/2025 07:56 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Oruka Therapeutics NASDAQ:ORKA

$15.44 +0.65 (+4.39%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.41 -0.03 (-0.19%)

As of 08/22/2025 04:10 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Tourmaline Bio NASDAQ:TRML

$23.31 +0.25 (+1.08%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$23.34 +0.03 (+0.13%)

As of 08/22/2025 05:42 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Tyra Biosciences NASDAQ:TYRA

$11.71 +0.01 (+0.09%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$11.70 -0.01 (-0.04%)

As of 08/22/2025 04:10 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time